AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio is a clinical-stage biotechnology company with a promising portfolio of immune cell modulating antibodies for autoimmune and inflammatory diseases, including two in late-stage development. This, combined with their recent partnership and potential for future revenue growth, makes AnaptysBio a strong candidate for long term investment. However, the ongoing legal dispute with GSK and Tesaro should be monitored closely, as it could impact the company's potential profits. Overall, AnaptysBio's focus on expanding royalty revenue and investing in new drug development puts them in a good position for growth in the future.

AnaptysBio is not the central catalyst in the development of imsidolimab for GPP, and they do not have responsibility for the final development or commercialization of the drug. They will only receive a minimal ongoing royalty and milestones from Vanda, who is primarily focused on GPP as their commercial infrastructure is established in inflammatory and dermatologic diseases. Additionally, there is litigation risk with GSK that could potentially result in a reduction or complete loss of AnaptysBio's royalty income, and any negative developments in Jemperli's commercial uptake or competition could negatively impact overall valuation.